9O Phase I/II, open-label, first-in-human study of the anti-GPC3 T cell engager SAR444200 in patients with advanced solid tumors: Updated safety and pharmacokinetic analysis
2025 · ESMO Open · 2 citations
https://doi.org/10.1016/j.esmoop.2025.104165
Sanofi (France)(FR)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
12
Papers
48
Citations
4
h-index
2
i10-index
Hélène Guillemin‐Paveau is an academic researcher from Sanofi (France). The author has contributed to research in topics: CAR-T cell therapy research & Monoclonal and Polyclonal Antibodies Research & Cancer Immunotherapy and Biomarkers. The author has an h-index of 4, co-authored 11 publications.
Click to start Chat